PREFACE

The Cochrane Handbook for Systematic Reviews of Interventions (the Handbook) provides guidance to authors for the preparation of Cochrane Intervention reviews (including Cochrane Overviews of reviews).

Keeping up to date

The Handbook is updated regularly to reflect advances in systematic review methodology and in response to feedback from users. Please refer to the following web site for the most recent version, for interim updates to the guidance and for details of previous versions of the Handbook.

www.cochrane.org/resources/handbook

Users of the Handbook are encouraged to send feedback and corrections to the Handbook editors; contact details are available on the web site.

Central sources of support

Present sources of support

The Cochrane Collaboration
Medical Research Council, United Kingdom
Department of Health and Ageing, Australia
Previous sources of support
National Health Service Research and Development Programme, United Kingdom
Health Research Board, Ireland
National Institute of Public Health, Norway
Copenhagen Hospital Corporation, Denmark
Health Services Research and Development Service and the University of Texas Health Science Center, San Antonio, USA
US Veterans Health Administration, USA
Oxford Regional Health Authority, UK
Nuffield Provincial Hospitals Trust, UK
LW Frohlich Fund, USA
Norwegian Ministry of Health and Social Affairs, Norway
Norwegian Research Council, Norway
Glaxo Wellcome, Norway

Acknowledgements
We are grateful to all past and current members of the Handbook Advisory Group for discussions and feedback, and would particularly like to thank Doug Altman, Chris Cates, Mike Clarke, Jon Deeks, Donna Gillies, Andrew Herxheimer, Harriet MacLehose, Philippa Middleton, Ruth Mitchell, David Moher, Donald Patrick, Ian Shemilt, Lesley Stewart, Jessica Thomas, Jane Tierney and Danielle Wheeler.

Many contributed constructive and timely peer review. We thank Phil Alderson, Claire Allen, Judith Anzures, Chris Cates, Jonathan Craig, Miranda Cumpston, Chris Del Mar, Kay Dickersin, Christian Gluud, Peter Gøtzsche, Frans Helmerhorst, Jini Hetherington, Sophie Hill, Sally Hopewell, Steve McDonald, David Moher, Ann Møller, Duncan Mortimer, Karen New, Denise O’Connor, Jordi Pardo, Rob Scholten, Simon Thompson, Jan Vandenbroucke, Janet Wale, Phil Wiffen, Hywel Williams, Paula Williamson, Jim Wright and Diana Wyatt.

Specific administrative support for this version of the Handbook was provided by Jane Lane. In addition, skilled and generous administrative and technical support provided by Claire Allen, Dave Booker, Jini Hetherington, Monica Kjeldstrøm, Cindy Manukonga, Rasmus Moustgaard, Jane Predl, Jacob Riis and Verena Roloff has contributed greatly to the preparation and co-ordination of this Handbook. We would also like to thank Lucy Sayer, Fiona Woods and Laura Mellor at Wiley-Blackwell for their patience, support and advice.

This major revision of the Handbook would not have been possible without the generous support provided to the editors by colleagues at the MRC Biostatistics Unit and the Institute of Public Health in Cambridge, UK and at the Australasian Cochrane Centre, Monash University, Australia.
The Handbook editors

Julian Higgins is a Senior Statistician at the MRC Biostatistics Unit, Institute of Public Health, University of Cambridge and a Visiting Fellow at the UK Cochrane Centre, Oxford, UK.

Sally Green is a Professorial Fellow at the Institute of Health Services Research at Monash University, Melbourne, Australia and Director of the Australasian Cochrane Centre.

Major contributors

Aquadro, Catherine
MAPI Research Institute
Lyon
France

Alderson, Philip
National Institute for Health and Clinical Excellence
London/Manchester
United Kingdom

Altman, Douglas G
Centre for Statistics in Medicine
University of Oxford
Oxford
United Kingdom

Armstrong, Rebecca
The McCaughey Centre: VicHealth Centre for the Promotion of Mental Health and Community Wellbeing
University of Melbourne
Melbourne
Australia

Askie, Lisa M
NHMRC Clinical Trials Centre
University of Sydney
Camperdown
Australia

Becker, Lorne A
Department of Family Medicine
SUNY Upstate Medical University
Syracuse, NY
United States of America

Berlin, Jesse A
Pharmacoepidemiology
Johnson & Johnson Pharmaceutical Research and Development
Titusville, NJ
USA

Booth, Andrew
School of Health and Related Research
University of Sheffield
Sheffield
United Kingdom

Byford, Sarah
Centre for the Economics of Mental Health
Institute of Psychiatry
King’s College London
London
United Kingdom

Clarke, Mike
UK Cochrane Centre
National Institute for Health Research
Oxford
United Kingdom

Deeks, Jonathan J
Department of Public Health and Epidemiology
University of Birmingham
Birmingham
United Kingdom

Doyle, Jodie
The McCaughey Centre: VicHealth Centre for the Promotion of Mental Health and Community Wellbeing
University of Melbourne
Melbourne
Australia

Drummond, Michael
Centre for Health Economics
University of York
York
United Kingdom

Egger, Matthias
Institute of Social and Preventive Medicine
University of Bern
Bern
Switzerland

Eisenstein, Eric
Duke Clinical Research Center
Duke University
Durham, NC
United States of America

Ghersi, Davina
Department of Research Policy and Cooperation
World Health Organization
Geneva
Switzerland

Glanville, Julie
Centre for Reviews and Dissemination
University of York
York
United Kingdom

Glasziou, Paul P
Department of Primary Health Care
University of Oxford
Oxford
United Kingdom

Green, Sally
Australasian Cochrane Centre
Monash University
Melbourne
Australia

Guyatt, Gordon H
Departments of Clinical Epidemiology and Biostatistics
McMaster University
Ontario
Canada

Hannes, Karin
Belgian Centre for Evidence-Based Medicine
Leuven
Belgium

Herxheimer, Andrew
Co-founder, DIPEx; Emeritus Fellow, UK Cochrane Centre
London
United Kingdom

Higgins, Julian PT
MRC Biostatistics Unit
Cambridge
United Kingdom

Knapp, Martin
Institute of Psychiatry
King’s College London
and
London School of Economics
London
United Kingdom

Lefebvre, Carol
UK Cochrane Centre
National Institute for Health Research
Oxford
United Kingdom

Loke, Yoon K
School of Medicine, Health Policy and Practice
University of East Anglia
Norwich
United Kingdom

Mallender, Jacqueline
Matrix Knowledge Group Ltd.
London
United Kingdom

Manheimer, Eric
Center for Integrative Medicine
University of Maryland School of Medicine
Baltimore, MA
United States of America

McDaid, David
Personal Social Services Research Unit
London School of Economics and Political Science
London
United Kingdom

Moher, David
Chalmers Research Group, Children’s Hospital of Eastern Ontario Research Institute; Department of Epidemiology and Community Medicine, University of Ottawa
Ottawa
Canada

Mugford, Miranda
Health Economics Group
School of Medicine, Health Policy and Practice
University of East Anglia
Norwich
United Kingdom

Noyes, Jane
Centre for Health-Related Research
School of Healthcare Sciences
Bangor University
Bangor
Wales
United Kingdom

O’Connor, Denise
Australasian Cochrane Centre
Monash University
Melbourne
Australia

Oxman, Andrew D
Preventive and International Health Care Unit
Norwegian Knowledge Centre for the Health Services
Oslo
Norway

Patrick, Donald L
Department of Health Services and Seattle Quality of Life Group
University of Washington
Seattle, WA
United States of America

Pearson, Alan
Joanna Briggs Institute
University of Adelaide
Adelaide
Australia

Popay, Jennie
Institute for Health Research
Lancaster University
Lancaster
United Kingdom

Price, Deirdre
Department of Clinical Pharmacology
University of Oxford
Oxford
United Kingdom

Reeves, Barnaby
Bristol Heart Institute
University of Bristol
Bristol
United Kingdom

Scholten, Rob
Dutch Cochrane Centre
Academic Medical Center
Amsterdam
The Netherlands

Schünemann, Holger J
INFORMA/CLARITY Research/Department of Epidemiology
National Cancer Institute Regina Elena
Rome
Italy

Shemilt, Ian
Health Economics Group
School of Medicine, Health Policy and Practice
University of East Anglia
Norwich
United Kingdom

Sterne, Jonathan AC
Department of Social Medicine
University of Bristol
Bristol
United Kingdom

Stewart, Lesley A
Centre for Reviews and Dissemination
University of York
York
United Kingdom

Tierney, Jayne F
MRC Clinical Trials Unit
London
United Kingdom

Vale, Luke
Health Economics Research Unit
University of Aberdeen
Aberdeen
United Kingdom

Vist, Gunn E
Preventive and International Health Care Unit
Norwegian Knowledge Centre for the Health Services
Oslo
Norway

Walker, Damian
Health Systems Program
Department of International Health
Johns Hopkins Bloomberg School of Public Health
Baltimore, MA
United States of America

Waters, Elizabeth
The McCaughey Centre: VicHealth Centre for the Promotion of Mental Health and Community Wellbeing
University of Melbourne
Melbourne
Australia

University of Ottawa
Ottawa
Ontario
Canada

Wells, George A
Department of Epidemiology and Community Medicine
Contents listing

1 Introduction
   1.1 The Cochrane Collaboration
      1.1.1 Introduction
         Box 1.1.a: The Principles of The Cochrane Collaboration
      1.1.2 Structure of The Cochrane Collaboration
      1.1.3 Publication of Cochrane reviews
         Box 1.1.b: Databases published in The Cochrane Library
   1.2 Systematic reviews
      1.2.1 The need for systematic reviews
      1.2.2 What is a systematic review?
   1.3 About this Handbook
   1.4 Contributors to the Handbook
   1.5 Chapter information
   1.6 References

2 Preparing a Cochrane review
   2.1 Rationale for protocols
   2.2 Format of a Cochrane review
      2.2.1 Rationale for the format of a Cochrane review
      2.2.2 Outline of a protocol for a Cochrane review
         Box 2.2.a: Sections of a protocol for a Cochrane review
      2.2.3 Detailed outline of a Cochrane review
         Box 2.2.b: Sections of a Cochrane review
   2.3 Logistics of doing a review
      2.3.1 Motivation for undertaking a review
      2.3.2 Planning the topic and scope of a review
      2.3.3 Registering a protocol
      2.3.4 The review team
         2.3.4.1 The importance of a team
         2.3.4.2 Consumer involvement
         2.3.4.3 Advisory groups
            Box 2.3.a: An example of the benefits of using an advisory group in the planning process
      2.3.5 Cochrane software for review authors and editorial bases of Cochrane Review Groups
      2.3.6 Training
      2.3.7 Editorial procedures of a Cochrane Review Group
      2.3.8 Resources for a systematic review
         Box 2.3.b: Timeline for a Cochrane review
      2.3.9 Seeking funding
   2.4 Publication of Cochrane reviews in print journals and books
   2.5 Publication of previously published reviews as Cochrane reviews
   2.6 Declaration of interest and commercial sponsorship
      Box 2.6.a The Cochrane Collaboration Code of Conduct for Avoiding Potential Financial Conflicts of Interest
   2.7 Chapter information
   2.8 References

3 Maintaining reviews: updates, amendments and feedback
   3.1 Introduction
      3.1.1 Why maintain a review?
      3.1.2 How frequently should a review be revisited?
   3.2 Some important definitions
3.2.1 Introduction
3.2.2 Updates and amendments:
  3.2.3 Citation versions of Cochrane reviews and protocols
    Box 3.2.a: Events leading to the creation of a Citation version of a Cochrane protocol or review
    Figure 3.2.a: Summary of changes to Cochrane reviews
    Figure 3.2.b: Summary of changes to Cochrane protocols
  3.2.4 Application of terms to Cochrane protocols
    3.2.4.1 Amendments to protocols
    3.2.4.2 New citation versions of protocols
      Box 3.2.b: Criteria for a new citation version of a Cochrane protocol
    3.2.4.3 Examples of changes to protocols that do not indicate a new citation version
  3.2.5 Application of terms to Cochrane reviews
    3.2.5.1 Updates of reviews
    3.2.5.2 Amendments to reviews
    3.2.5.3 New citation versions of reviews
      Box 3.2.c: Criteria for a new citation version of a Cochrane review
    3.2.5.4 Examples of changes to reviews that do not indicate a new citation version
3.3 Important dates associated with Cochrane reviews
  3.3.1 Introduction
  3.3.2 Date review assessed as up to date
    Box 3.3.a: Guidance for declaring a review as being up to date
  3.3.3 Date of search
  3.3.4 Date next stage expected
  3.3.5 Date of last edit
  3.3.6 Date declared review no longer needs to be updated
3.4 Considerations when updating a Cochrane review
  3.4.1 Where to start
  3.4.2 Updating a review with an unchanged review question
    3.4.2.1 Re-executing the search
    3.4.2.2 Updating reviews when no new studies are found
    3.4.2.3 Updating reviews when new studies are found
  3.4.3 Revising review questions and selection criteria
  3.4.4 Splitting reviews
  3.4.5 Amending the methodology of a review
  3.4.6 Other changes to the review
  3.4.7 Editorial process
3.5 ‘What’s new’ tables and History
  3.5.1 What’s new events
  3.5.2 Completing the ‘What’s new’ table
    Table 3.5.a: Available ‘What’s new’ events for protocols
    Table 3.5.b: Available ‘What’s new’ events for reviews
  3.5.3 History table
3.6 Incorporating and addressing feedback in a Cochrane review
3.7 Chapter information
3.8 References

4 Guide to the contents of a Cochrane protocol and review
  4.1 Introduction
  4.2 Title and review information (or protocol information)
    4.2.1 Title
      Table 4.2.a: Structure for Cochrane review titles
    4.2.2 Authors
    4.2.3 Contact person
    4.2.4 Dates
    4.2.5 What’s New and History
4.3 Abstract
4.4 Plain language summary
4.5 Main text
4.6 Tables
  4.6.1 Characteristics of included studies
  4.6.2 Risk of bias
  4.6.3 Characteristics of excluded studies
  4.6.4 Characteristics of studies awaiting classification
  4.6.5 Characteristics of ongoing studies
  4.6.6 Summary of findings tables
  4.6.7 Additional tables
4.7 Studies and references
  4.7.1 References to studies
  4.7.2 Other references
4.8 Data and analyses
  Figure 4.8.a: Illustration of the hierarchy of the ‘Data and analyses’ section.
4.9 Figures
  Table 4.9.a: Types of figures that can be included in a Cochrane review
  4.9.1 RevMan plots and graphs
  4.9.2 Other figures
4.10 Sources of support to the review
4.11 Feedback
4.12 Appendices
4.13 Chapter information
4.14 References

5 Defining the review question and developing criteria for including studies
  5.1 Rationale for well-formulated questions
    5.1.1 Eligibility criteria
  5.2 Defining types of participants: which people and populations?
    Box 5.2.a: Factors to consider when developing criteria for ‘Types of participants’
  5.3 Defining types of interventions: which comparisons to make?
    Box 5.3.a: Factors to consider when developing criteria for ‘Types of interventions’
  5.4 Defining types of outcomes: which outcome measures are most important?
    5.4.1 Listing relevant outcomes
    5.4.2 Prioritizing outcomes: Main, primary and secondary outcomes
      Box 5.4.a: Factors to consider when developing criteria for ‘Types of outcomes’
    5.4.3 Adverse outcomes
    5.4.4 Economic data
  5.5 Defining types of study
  5.6 Defining the scope of a review question (broad versus narrow)
    Table 5.6.a: Some advantages and disadvantages of broad versus narrow review questions
  5.7 Changing review questions
  5.8 Chapter information
  5.9 References

6 Searching for studies
  6.1 Introduction
    6.1.1 General issues
      6.1.1.1 Role of the Trials Search Co-ordinator
      6.1.1.2 Minimizing bias
      6.1.1.3 Studies versus reports of studies
      6.1.1.4 Copyright
    6.1.2 Summary points
  6.2 Sources to search
6.2.1 Bibliographic databases
   6.2.1.1 Bibliographic databases – general introduction
   6.2.1.2 The Cochrane Central Register of Controlled Trials (CENTRAL)
   6.2.1.3 MEDLINE and EMBASE
   6.2.1.4 National and regional databases
      Box 6.2.a: Examples of regional electronic bibliographic databases
   6.2.1.5 Subject-specific databases
      Box 6.2.b: Examples of subject-specific electronic bibliographic databases
   6.2.1.6 Citation indexes
   6.2.1.7 Dissertations and theses databases
      Box 6.2.c: Examples of dissertations and theses databases
   6.2.1.8 Grey literature databases
6.2.2 Journals and other non-bibliographic-database sources
   6.2.2.1 Handsearching
   6.2.2.2 Full-text journals available electronically
      Box 6.2.d: Examples of full-text journal sources available worldwide without charge
   6.2.2.3 Tables of contents
      Box 6.2.e: Examples of organizations offering Table of Contents (TOC) services
   6.2.2.4 Conference abstracts or proceedings
      Box 6.2.f: Examples of specialist conference abstract sources
   6.2.2.5 Other reviews, guidelines and reference lists as sources of studies
      Box 6.2.g: Examples of evidence-based guidelines
   6.2.2.6 Web searching
6.2.3 Unpublished and ongoing studies
   6.2.3.1 National and international trials registers
      Box 6.2.h: Examples of national and international trials registers
   6.2.3.2 Subject-specific trials registers
   6.2.3.3 Pharmaceutical industry trials registers
      Box 6.2.i: Examples of pharmaceutical industry trials registers
   6.2.3.4 Trials results registers and other sources
      Box 6.2.j: Examples of trials results registers
6.2.4 Summary points
6.3 Planning the search process
   6.3.1 Involving Trials Search Co-ordinators and healthcare librarians in the search process
   6.3.2 Collaboration-wide search initiatives
      Figure 6.3.a: Illustration of the contents of CENTRAL
   6.3.2.1 What is in The Cochrane Central Register of Controlled Trials (CENTRAL) from MEDLINE?
      Box 6.3.a: Cochrane definitions and criteria for randomized controlled trials (RCTs) and controlled clinical trials (CCTs)
      Box 6.3.b: US National Library of Medicine 2008 definitions for the Publication Type terms ‘Randomized Controlled Trial’ and ‘Controlled Clinical Trial’
   6.3.2.2 What is in The Cochrane Central Register of Controlled Trials (CENTRAL) from EMBASE?
   6.3.2.3 What is in The Cochrane Central Register of Controlled Trials (CENTRAL) from other databases and handsearching?
   6.3.2.4 What is in The Cochrane Central Register of Controlled Trials (CENTRAL) from Specialised Registers of Cochrane Review Groups and Fields?
6.3 Searching CENTRAL, MEDLINE and EMBASE: specific issues
   6.3.3.1 Searching The Cochrane Central Register of Controlled Trials (CENTRAL): specific issues
      Box 6.3.c: Example of exclusion of MEDLINE and EMBASE records when searching CENTRAL
   6.3.3.2 Searching MEDLINE and EMBASE: specific issues
6.3.4 Summary points
6.4 Designing search strategies
6.4.1 Designing search strategies – an introduction
6.4.2 Structure of a search strategy
6.4.3 Service providers and search interfaces
6.4.4 Sensitivity versus precision
6.4.5 Controlled vocabulary and text words
6.4.6 Synonyms, related terms, variant spellings, truncation and wildcards
6.4.7 Boolean operators (AND, OR and NOT)
   Figure 6.4.a: Combining concepts as search sets
6.4.8 Proximity operators (NEAR, NEXT and ADJ)
6.4.9 Language, date and document format restrictions
6.4.10 Identifying fraudulent studies, other retracted publications, errata and comments
6.4.11 Search filters
   6.4.11.1 The Cochrane Highly Sensitive Search Strategies for identifying randomized trials in MEDLINE
   6.4.11.2 Search filters for identifying randomized trials in EMBASE
6.4.12 Updating searches
6.4.13 Demonstration search strategies
   Box 6.4.e: Demonstration search strategy for the CENTRAL, for the topic ‘Tamoxifen for breast cancer’
   Box 6.4.f: Demonstration search strategy for the MEDLINE (Ovid format), for the topic ‘Tamoxifen for breast cancer’
6.4.14 Summary points
6.5 Managing references
   6.5.1 Bibliographic software
   6.5.2 Which fields to download
      Box 6.5.a: Important field labels in PubMed
   6.5.3 Summary points
6.6 Documenting and reporting the search process
   6.6.1 Documenting the search process
   6.6.2 Reporting the search process in the review
      6.6.2.1 Reporting the search process in the protocol
      6.6.2.2 Reporting the search process in the review
   6.6.3 Summary points
6.7 Chapter information
6.8 References

7 Selecting studies and collecting data
7.1 Introduction
7.2 Selecting studies
   7.2.1 Studies (not reports) as the unit of interest
   7.2.2 Identifying multiple reports from the same study
   7.2.3 A typical process for selecting studies
   7.2.4 Implementation of the selection process
   7.2.5 Selecting ‘excluded studies’
   7.2.6 Measuring agreement
      7.2.6.1 Calculations for a simple kappa statistic
7.3 What data to collect
   7.3.1 What are data?
   7.3.2 Methods and potential sources of bias
   7.3.3 Participants and setting
   7.3.4 Interventions
      7.3.4.1 Integrity of interventions
   7.3.5 Outcome measures
      7.3.5.1 Adverse outcomes
   7.3.6 Results
7.3.7 Other information to collect
7.4 Sources of data
  7.4.1 Reports
  7.4.2 Correspondence with investigators
  7.4.3 Individual patient data
7.5 Data collection forms
  7.5.1 Rationale for data collection forms
  7.5.2 Electronic versus paper data collection forms
  7.5.3 Design of a data collection form
  7.5.4 Coding and explanations
7.6 Extracting data from reports
  7.6.1 Introduction
  7.6.2 Who should extract data?
  7.6.3 Preparing for data extraction
  7.6.4 Extracting data from multiple reports of the same study
  7.6.5 Reliability and reaching consensus
  7.6.6 Summary
7.7 Extracting study results and converting to the desired format
  7.7.1 Introduction
  7.7.2 Data extraction for dichotomous outcomes
  7.7.3 Data extraction for continuous outcomes
    7.7.3.1 Post-intervention versus change from baseline
    7.7.3.2 Obtaining standard deviations from standard errors and confidence intervals for group means
    7.7.3.3 Obtaining standard deviations from standard errors, confidence intervals, t values and P values for differences in means
    7.7.3.4 Transformations and skewed data
    7.7.3.5 Medians and interquartile ranges
    7.7.3.6 Ranges
    7.7.3.7 No information on variability
    7.7.3.8 Combining groups
  7.7.4 Data extraction for ordinal outcomes
  7.7.5 Data extraction for counts
    7.7.5.1 Extracting counts as dichotomous data
    7.7.5.2 Extracting counts as continuous data
    7.7.5.3 Extracting counts as time-to-event data
    7.7.5.4 Extracting counts as rate data
  7.7.6 Data extraction for time-to-event outcomes
  7.7.7 Data extraction for estimates of effects
    7.7.7.1 Effect estimates and generic inverse variance meta-analysis
    7.7.7.2 Obtaining standard errors from confidence intervals and P values: absolute (difference) measures
    7.7.7.3 Obtaining standard errors from confidence intervals and P values: ratio measures
7.8 Managing data
7.9 Chapter information
7.10 References

8 Assessing risk of bias in included studies
  8.1 Introduction
  8.2 What is bias?
    8.2.1 ‘Bias’ and ‘risk of bias’
    8.2.2 ‘Risk of bias’ and ‘quality’
    8.2.3 Establishing empirical evidence of biases
  8.3 Tools for assessing quality and risk of bias
    8.3.1 Types of tools
8.3.2 Reporting versus conduct
8.3.3 Quality scales and Cochrane reviews
8.3.4 Collecting information for assessments of risk of bias
8.4 Introduction to sources of bias in clinical trials
  Table 8.4.a: A common classification scheme for bias
8.5 The Cochrane Collaboration’s tool for assessing risk of bias
  8.5.1 Overview
  Table 8.5.a: The Cochrane Collaboration’s tool for assessing risk of bias
  8.5.2 The description
  Table 8.5.b: Examples of summary descriptions for Sequence generation entry
  8.5.3 The judgement
  Table 8.5.c: Criteria for judging risk of bias in the ‘Risk of bias’ assessment tool
8.6 Presentation of assessments of risk of bias
  Figure 8.6.a: Example of a ‘Risk of bias’ table for a single study (fictional)
  Figure 8.6.b: Example of a ‘Risk of bias graph’
  Figure 8.6.c: Example of a ‘Risk of bias summary’
8.7 Summary assessments of risk of bias
  Table 8.7.a: Possible approach for summary assessments of the risk of bias for each important outcome (across domains) within and across studies
8.8 Incorporating assessments into analyses
  8.8.1 Introduction
  8.8.2 Exploring the impact of risk of bias
    8.8.2.1 Graphing results according to risk of bias
    8.8.2.2 Studies assessed as at unclear risk of bias
    8.8.2.3 Meta-regression and comparisons of subgroups
  8.8.3 Including ‘risk of bias’ assessments in analyses
    8.8.3.1 Possible analysis strategies
  8.8.4 Other methods for addressing risk of bias
    8.8.4.1 Direct weighting
    8.8.4.2 Bayesian approaches
8.9 Sequence generation
  8.9.1 Rationale for concern about bias
  8.9.2 Assessing risk of bias in relation to adequate or inadequate sequence generation
    8.9.2.1 Adequate methods of sequence generation
    8.9.2.2 Inadequate methods of sequence generation
    8.9.2.3 Methods of sequence generation with unclear risk of bias
8.10 Allocation sequence concealment
  8.10.1 Rationale for concern about bias
  8.10.2 Assessing risk of bias in relation to adequate or inadequate allocation sequence concealment
    8.10.2.1 Adequate methods of allocation sequence concealment
    Table 8.10.a: Minimal and extended criteria for judging concealment of allocation sequence to be adequate (low risk of bias)
8.11 Blinding of participants, personnel and outcome assessors
  8.11.1 Rationale for concern about bias
  8.11.2 Assessing risk of bias in relation to adequate or inadequate blinding
8.12 Incomplete outcome data
  8.12.1 Rationale for concern about bias
  8.12.2 Assessing risk of bias from incomplete outcome data
    8.12.2.1 Low risk of bias due to incomplete outcome data
    8.12.2.2 High risk of bias due to incomplete outcome data
    8.12.2.3 Attempts to address missing data in reports: imputation
8.13 Selective outcome reporting
  8.13.1 Rationale for concern about bias
  8.13.2 Assessing risk of bias from selective reporting of outcomes
8.14 Other potential threats to validity
  8.14.1 Rationale for concern about bias
9 Analysing data and undertaking meta-analyses

9.1 Introduction
9.1.1 Do not start here!
9.1.2 Planning the analysis
9.1.3 Why perform a meta-analysis in a review?
9.1.4 When not to use meta-analysis in a review
9.1.5 What does a meta-analysis entail?
9.1.6 Which comparisons should be made?
9.1.7 Writing the analysis section of the protocol

9.2 Types of data and effect measures
9.2.1 Types of data
9.2.2 Effect measures for dichotomous outcomes
   Box 9.2.a: Calculation of risk ratio (RR), odds ratio (OR) and risk difference (RD) from a 2x2 table
   9.2.2.1 Risk and odds
   9.2.2.2 Measures of relative effect: the risk ratio and odds ratio
   9.2.2.3 Warning: OR and RR are not the same
   9.2.2.4 Measure of absolute effect: the risk difference
   9.2.2.5 What is the event?
9.2.3 Effect measures for continuous outcomes
   9.2.3.1 The mean difference (or difference in means)
   9.2.3.2 The standardized mean difference
9.2.4 Effect measures for ordinal outcomes and measurement scales
9.2.5 Effect measures for counts and rates
   9.2.5.1 Warning: counting events or counting participants?
9.2.6 Effect measures for time-to-event (survival) outcomes
9.2.7 Expressing intervention effects on log scales

9.3 Study designs and identifying the unit of analysis
9.3.1 Unit-of-analysis issues
9.3.2 Cluster-randomized trials
9.3.3 Cross-over trials
9.3.4 Repeated observations on participants
9.3.5 Events that may re-occur
9.3.6 Multiple treatment attempts
9.3.7 Multiple body parts I: body parts receive the same intervention
9.3.8 Multiple body parts II: body parts receive different interventions
9.3.9 Multiple intervention groups

9.4 Summarizing effects across studies
9.4.1 Meta-analysis
9.4.2 Principles of meta-analysis
9.4.3 A generic inverse-variance approach to meta-analysis
    9.4.3.1 Random-effects (DerSimonian and Laird) method for meta-analysis
    9.4.3.2 The generic inverse variance outcome type in RevMan
9.4.4 Meta-analysis of dichotomous outcomes
    9.4.4.1 Mantel-Haenszel methods
9.4.4.2 Peto odds ratio method
9.4.4.3 Random-effects method
9.4.4.4 Which measure for dichotomous outcomes?
9.4.5 Meta-analysis of continuous outcomes
9.4.5.1 Which measure for continuous outcomes?
9.4.5.2 Meta-analysis of change scores
9.4.5.3 Meta-analysis of skewed data
9.4.6 Combining dichotomous and continuous outcomes
9.4.7 Meta-analysis of ordinal outcomes and measurement scales
9.4.8 Meta-analysis of counts and rates
9.4.9 Meta-analysis of time-to-event outcomes
9.4.10 A summary of meta-analysis methods available in RevMan
  Table 9.4.a: Summary of meta-analysis methods available in RevMan
9.4.11 Use of vote counting for meta-analysis
9.5 Heterogeneity
9.5.1 What is heterogeneity?
9.5.2 Identifying and measuring heterogeneity
9.5.3 Strategies for addressing heterogeneity
9.5.4 Incorporating heterogeneity into random-effects models
9.6 Investigating heterogeneity
9.6.1 Interaction and effect modification
9.6.2 What are subgroup analyses?
9.6.3 Undertaking subgroup analyses
  9.6.3.1 Is the effect different in different subgroups?
9.6.4 Meta-regression
9.6.5 Selection of study characteristics for subgroup analyses and meta-regression
  9.6.5.1 Ensure that there are adequate studies to justify subgroup analyses and meta-regressions
  9.6.5.2 Specify characteristics in advance
  9.6.5.3 Select a small number of characteristics
  9.6.5.4 Ensure there is scientific rationale for investigating each characteristic
  9.6.5.5 Be aware that the effect of a characteristic may not always be identified
  9.6.5.6 Think about whether the characteristic is closely related to another characteristic (confounded)
9.6.6 Interpretation of subgroup analyses and meta-regressions
9.6.7 Investigating the effect of baseline risk
9.6.8 Dose-response analyses
9.7 Sensitivity analyses
9.8 Chapter information
  Box 9.8.a: The Cochrane Statistical Methods Group
9.9 References

10 Addressing reporting biases
10.1 Introduction
  Table 10.1.a: Definitions of some types of reporting biases
10.2 Types of reporting biases and the supporting evidence
  10.2.1 Publication bias
    Figure 10.2.a: Cumulative full publication of results initially presented as abstracts from 45 studies reporting time to publication that followed up research presented at meetings and conferences
    Table 10.2.a: Publication status of five cohorts of research projects approved by ethics committees or institutional review boards which had been completed and analysed at the time of follow up.
      (Adapted from Hopewell et al., (Hopewell 2008)).
    Figure 10.2.b: Publication bias in clinical trials due to statistical significance or direction of trial results (adapted from Hopewell et al. (Hopewell 2008)).
  10.2.1.1 Time lag bias
  10.2.1.2 Who is responsible for publication bias?
10.1.3 The influence of external funding and commercial interests
10.2 Other reporting biases
10.2.1 Duplicate (multiple) publication bias
10.2.2 Location bias
10.2.3 Citation bias
10.3 Avoiding reporting biases
10.3.1 Implications of the evidence concerning reporting biases
10.3.2 Including unpublished studies in systematic reviews
10.3.3 Trial registries and publication bias
10.4 Detecting reporting biases
10.4.1 Funnel plots
10.4.2 Different reasons for funnel plot asymmetry
10.4.3 Tests for funnel plot asymmetry
10.4.4 Sensitivity analyses
10.5 Chapter information
10.6 References

11 Presenting results and ‘Summary of findings’ tables
11.1 Introduction
11.2 Characteristics of included studies tables
11.3 Data and analyses
11.3.1 The ‘Data and analyses’ section of a review
11.3.2 Forest plots
11.3.2.1 Forest plots in RevMan
11.3.3 Other data tables
11.4 Figures
11.4.1 Types of figures
11.4.2 Selecting RevMan analyses as figures
11.4.3 Additional figures
11.5 ‘Summary of findings’ tables
11.5.1 Introduction to ‘Summary of findings’ tables
11.5.2 Selecting outcomes for ‘Summary of findings’ tables
11.5.3 General template for ‘Summary of findings’ tables
11.5.4 Producing ‘Summary of findings’ tables
11.5.5 Statistical considerations in ‘Summary of findings’ tables
11.5.6 Detailed contents of a ‘Summary of findings’ table
   11.5.6.1 Table title and header
   11.5.6.2 Outcomes
   11.5.6.3 Illustrative comparative risks 1: Assumed risk (with control intervention)
   11.5.6.4 Illustrative comparative risks 2: Corresponding risk (with experimental intervention)
   11.5.6.5 Relative effect (95% CI)
   11.5.6.6 Number of participants (studies)
   11.5.6.7 Quality of the evidence (GRADE)
   11.5.6.8 Comments

11.6 Additional tables

11.7 Presenting results in the text
   11.7.1 Results of meta-analyses
   11.7.2 Results without meta-analyses

11.8 Writing an abstract
   Box 11.8.a: Hypothetical example of an abstract

11.9 Writing a plain language summary
   11.9.1 About plain language summaries
   11.9.2 Plain language title
   11.9.3 Summary text

11.10 Chapter information

12 Interpreting results and drawing conclusions

12.1 Introduction

12.2 Assessing the quality of a body of evidence
   12.2.1 The GRADE approach
       Table 12.2.a: Levels of quality of a body of evidence in the GRADE approach
       Table 12.2.b: Factors that may decrease the quality level of a body of evidence
       Table 12.2.c: Factors that may increase the quality level of a body of evidence
   12.2.2 Factors that decrease the quality level of a body of evidence
       Table 12.2.d: Further guidelines for factor 1 (of 5) in a GRADE assessment: Going from assessments of risk of bias to judgments about study limitations for main outcomes
   12.2.3 Factors that increase the quality level of a body of evidence

12.3 Issues in applicability
   12.3.1 The role of the review author
   12.3.2 Biologic variation
   12.3.3 Variation in context and culture
   12.3.4 Variation in adherence
   12.3.5 Variation in values and preferences

12.4 Interpreting results of statistical analyses
   12.4.1 Confidence intervals
   12.4.2 P values and statistical significance

12.5 Interpreting results from dichotomous outcomes (including numbers needed to treat)
   12.5.1 Relative and absolute risk reductions
   12.5.2 More about the number needed to treat (NNT)
   12.5.3 Expressing absolute risk reductions
   12.5.4 Computations
       12.5.4.1 Computing NNT from a risk difference (RD)
       12.5.4.2 Computing absolute risk reduction or NNT from a risk ratio (RR)
       12.5.4.3 Computing absolute risk reduction or NNT from an odds ratio (OR)
       12.5.4.4 Computing risk ratio from an odds ratio (OR)
       12.5.4.5 Computing confidence limits

12.6 Interpreting results from continuous outcomes (including standardized mean differences)
   12.6.1 Meta-analyses with continuous outcomes
   12.6.2 Re-expressing SMDs using rules of thumb for effect sizes
12.6.3 Re-expressing SMDs by transformation to odds ratio

Table 12.6.a: NNTs equivalent to specific SMDs for various given ‘proportions improved’ in the control group

12.6.4 Re-expressing SMDs using a familiar instrument

12.7 Drawing conclusions

12.7.1 Conclusions sections of a Cochrane review

12.7.2 Implications for practice

12.7.3 Implications for research

12.7.4 Common errors in reaching conclusions

12.8 Chapter information

Box 12.8.a: Cochrane Applicability and Recommendations Methods Group

12.9 References

13 Including non-randomized studies

13.1 Introduction

13.1.1 What this chapter is about

Box 13.1.a: Some types of NRS design used for evaluating the effects of interventions

13.1.2 Why consider non-randomized studies?

13.1.3 Key issues about the inclusion of non-randomized studies in a Cochrane review

13.1.4 The importance of a protocol for a Cochrane review that includes non-randomized studies

13.1.5 Structure of subsequent sections in the chapter

13.2 Developing criteria for including non-randomized studies

13.2.1 What is different when including non-randomized studies?

13.2.1.1 Including both randomized and non-randomized studies

13.2.1.2 Evaluating benefits and harms

13.2.1.3 Determining which types of non-randomized study to include

13.2.1.4 Distinguishing between aetiology and effectiveness research questions

13.2.2 Guidance and resources available to support review authors

13.2.3 Summary

Table 13.2.a: List of study design features (studies with allocation to interventions at the individual level)

Table 13.2.b: List of study design features (studies with allocation to interventions at the group level)

13.3 Searching for non-randomized studies

13.3.1 What is different when including non-randomized studies?

13.3.1.1 Comprehensiveness of search strategy

13.3.1.2 Identifying NRS in searches

13.3.1.3 Reviewing citations / abstracts

13.3.2 Guidance and resources available to support review authors

13.3.3 Summary

13.4 Selecting studies and collecting data

13.4.1 What is different when including non-randomized studies?

13.4.2 Guidance and resources available to support review authors

Box 13.4.a: User guide for data collection/study assessment using checklist in Table 13.2.a or Table 13.2.a

13.4.3 Summary

13.5 Assessing risk of bias in non-randomized studies

13.5.1 What is different when including non-randomized studies?

13.5.1.1 Sources of bias in non-randomized studies

13.5.1.2 Evidence of risk of bias in non-randomized studies

13.5.2 Guidance and resources available to support review authors

13.5.2.1 General considerations in assessing risk of bias in non-randomized studies

13.5.2.2 Confounding and adjustment

13.5.2.3 Tools for assessing methodological quality or risk of bias in non-randomized studies

13.5.2.4 Practical limitations in assessing risk of bias in non-randomized studies
13.5.3 Summary

13.6 Synthesis of data from non-randomized studies
   13.6.1 What is different when including non-randomized studies?
   13.6.2 Guidance and resources available to support review authors
      13.6.2.1 Controlling for confounding
      13.6.2.2 Combining studies
      13.6.2.3 Analysis of heterogeneity
      13.6.2.4 When pooling is judged not to be appropriate
   13.6.3 Summary

13.7 Interpretation and discussion
   13.7.1 Challenges in interpreting Cochrane reviews of effectiveness that include non-randomized studies
      13.7.1.1 Have all important and relevant studies been included?
      13.7.1.2 Has the risk of bias to included studies been adequately assessed?
   13.7.2 Evaluating the strength of evidence provided by reviews that include non-randomized studies
   13.7.3 Guidance for potential review authors

13.8 Chapter information
   Box 13.8.a: The Cochrane Non-Randomised Studies Methods Group

13.9 References

14 Adverse effects
   14.1 Introduction
      14.1.1 The need to consider adverse effects
      14.1.2 Concepts and terminology
      14.1.3 When it is most important to consider adverse effects
      Table 14.1.a: Contexts and examples warranting detailed examination of adverse effects
   14.2 Scope of a review addressing adverse effects
      14.2.1 Identical methods for beneficial and adverse effects
      14.2.2 Different methods for beneficial and adverse effects
      14.2.3 Separate review for adverse effects
   14.3 Choosing which adverse effects to include
      14.3.1 Narrow versus broad focus
      14.3.2 Withdrawal or drop-out as an outcome measure for adverse effects
   14.4 Types of studies
   14.5 Search methods for adverse effects
      14.5.1 Sources of information on adverse effects of drugs
      14.5.2 Search strategy for adverse effects
      14.5.2.1 Searching electronic databases for adverse effects using index terms
      14.5.2.2 Searching electronic databases for adverse effects using free-text terms
   14.6 Assessing risk of bias for adverse effects
      14.6.1 Clinical trials
      14.6.2 Case-control and cohort studies
      14.6.3 Case reports
   14.7 Chapter information
      Box 14.7.a: The Cochrane Adverse Effects Methods Group
   14.8 References

15 Incorporating economics evidence
   15.1 The role and relevance of economics evidence in Cochrane reviews
      15.1.1 Introduction
      Box 15.1.a: Archie Cochrane on health economics (Cochrane 1972)
      15.1.2 Economics and economic evaluation
      Box 15.1.b: Types of full economic evaluation
      15.1.3 Coverage of economics issues in Cochrane reviews
   15.2 Planning the economics component of a Cochrane review
15.2.1 Formulating an economics question
  Figure 15.2.a: Clinical event pathways
  Box 15.2.a: Background commentary highlighting economics aspects of interventions
15.2.2 Including measures of resource use, costs and cost-effectiveness as outcomes
15.2.3 Specifying types of health economics studies and the scope of the economics component of a review

15.3 Locating studies
  15.3.1 Use of electronic search filters
  15.3.2 Use of specialist databases

15.4 Selecting studies and collecting data
  15.4.1 Assessing relevance to the review topic
  15.4.2 Collecting data

15.5 Addressing risk of bias
  15.5.1 Classification of studies by study design
  15.5.2 Critical appraisal of methodological quality
    Figure 15.5.a: Drummond checklist (Drummond 1996)
    Figure 15.5.b: Evers checklist (Evers 2005)

15.6 Analysing and presenting results
  15.6.1 Presenting results in tables
  15.6.2 Narrative summary of results
  15.6.3 Meta-analysis of resource use and cost data
    Box 15.6.a: Statement of a decision not to conduct a meta-analysis of resource use or cost data
  15.6.4 Developing an economic model

15.7 Addressing reporting biases

15.8 Interpreting results
  Box 15.8.a: Highlighting a need for further economics studies in conclusions

15.9 Conclusions

15.10 Chapter information
  Box 15.10.a: The Campbell and Cochrane Economics Methods Group

15.11 References

16 Special topics in statistics

16.1 Missing data
  16.1.1 Types of missing data
    Table 16.1.a: Types of missing data in a meta-analysis
  16.1.2 General principles for dealing with missing data
  16.1.3 Missing standard deviations
    16.1.3.1 Imputing standard deviations
    16.1.3.2 Imputing standard deviations for changes from baseline

16.2 Intention-to-treat issues
  16.2.1 Introduction
  16.2.2 Intention-to-treat issues for dichotomous data
  16.2.3 Intention-to-treat issues for continuous data
  16.2.4 Conditional outcomes only available for subsets of participants

16.3 Cluster-randomized trials
  16.3.1 Introduction
  16.3.2 Assessing risk of bias in cluster-randomized trials
  16.3.3 Methods of analysis for cluster-randomized trials
  16.3.4 Approximate analyses of cluster-randomized trials for a meta-analysis: effective sample sizes
  16.3.5 Example of incorporating a cluster-randomized trial
  16.3.6 Approximate analyses of cluster-randomized trials for a meta-analysis: inflating standard errors
  16.3.7 Issues in the incorporation of cluster-randomized trials
  16.3.8 Individually randomized trials with clustering

16.4 Cross-over trials
16.4.1 Introduction
16.4.2 Assessing suitability of cross-over trials
16.4.3 Assessing risk of bias in cross-over trials
16.4.4 Methods of analysis for cross-over trials
16.4.5 Methods for incorporating cross-over trials into a meta-analysis
16.4.6 Approximate analyses of cross-over trials for a meta-analysis
  Table 16.4.a: Some possible data available from the report of a cross-over trial
    16.4.6.1 Mean differences
    16.4.6.2 Standardized mean difference
    16.4.6.3 Imputing correlation coefficients
    16.4.6.4 Example
16.4.7 Issues in the incorporation of cross-over trials
16.5 Studies with more than two intervention groups
  16.5.1 Introduction
  16.5.2 Determining which intervention groups are relevant
  16.5.3 Assessing risk of bias in studies with more than two groups
  16.5.4 How to include multiple groups from one study
  16.5.5 Heterogeneity considerations with multiple-intervention studies
  16.5.6 Factorial trials
16.6 Indirect comparisons and multiple-treatments meta-analysis
  16.6.1 Introduction
  16.6.2 Indirect comparisons
  16.6.3 Multiple-treatments meta-analysis
16.7 Multiplicity and the play of chance
  16.7.1 Introduction
  16.7.2 Multiplicity in systematic reviews
16.8 Bayesian and hierarchical approaches to meta-analysis
  16.8.1 Bayesian methods
  16.8.2 Hierarchical models
16.9 Rare events (including zero frequencies)
  16.9.1 Meta-analysis of rare events
  16.9.2 Studies with zero-cell counts
  16.9.3 Studies with no events
  16.9.4 Confidence intervals when no events are observed
  16.9.5 Validity of methods of meta-analysis for rare events
16.10 Contributions to this chapter
16.11 References

17 Patient-reported outcomes
17.1 What are patient-reported outcomes?
  Figure 17.1.a: Classification of clinical trial outcomes with illustration of those most important to patients
17.2 Patient-reported outcomes and Cochrane reviews
17.3 Health status and quality of life as PRO outcomes
  Table 17.3.a: Definitions of selected terms related to quality of life
  Table 17.3.b: A taxonomy of health status and quality of life measures adapted from Patrick and Erickson (Patrick 1993).
17.4 Issues in the measurement of patient-reported outcomes
  17.4.1 Validity of instruments
  17.4.2 Ability of an instrument to measure change
17.5 Locating and selecting studies with patient-reported outcomes
17.6 Assessing and describing patient-reported outcomes
  Table 17.6.a: A checklist for describing and assessing PROs in clinical trials
17.7 Comparability of different patient-reported outcome measures
17.8 Interpreting Results
17.8.1 Study summaries focusing on a single patient-reported outcome
17.8.2 Study summaries using more than one patient-reported outcome
17.8.3 When studies do not address patient-reported outcomes
17.9 Chapter information
   Box 17.9.a: The Cochrane Patient Reported Outcomes Methods Group
17.10 References

18 Reviews of individual patient data
18.1 Introduction
   18.1.1 What is an IPD review?
   18.1.2 When should an IPD review be done?
      Box 18.1.a: Potential benefits of IPD
   18.1.3 How are IPD review methods different?
   18.1.4 How are IPD reviews organized?
   18.1.5 What healthcare areas have used the IPD approach?
   18.1.6 If I am thinking about doing an IPD review, what should I do first?
18.2 The collaborative nature of IPD meta-analyses
   18.2.1 Collaborative groups
   18.2.2 Negotiating collaboration
   18.2.3 Confidentiality
18.3 Dealing with data
   18.3.1 Deciding what data to collect
   18.3.2 Data format
   18.3.3 Re-coding and re-defining supplied variables
   18.3.4 Checking data supplied
      18.3.4.1 Checking for missing or duplicated data
      18.3.4.2 Checking plausibility
      18.3.4.3 Checking randomization
      18.3.4.4 Checking information is up to date
18.4 Analysis
   18.4.1 Analysis advantages
   18.4.2 General approach
   18.4.3 Time-to-event analyses
   18.4.4 Bringing analyses up to date: long-term outcomes
   18.4.5 Subgroup analysis
   18.4.6 Additional analyses
   18.4.7 Software
18.5 Limitations and Caveats
   18.5.1 What an IPD review cannot fix
   18.5.2 Unavailable studies
   18.5.3 Deciding when an IPD review is appropriate
18.6 Chapter information
   Box 18.6.a: The Cochrane Individual Patient Data Meta-analysis Methods Group.
18.7 References

19 Prospective meta-analysis
19.1 Introduction
   19.1.1 What is a prospective meta-analysis (PMA)?
   19.1.2 What is the difference between a PMA and a large multi-centre trial?
   19.1.3 What healthcare areas have used the PMA approach?
   19.1.4 What resources do I need?
19.2 The collaborative nature of PMA
   19.2.1 Collaborative groups
   19.2.2 Negotiating collaboration
   19.2.3 Confidentiality
19.3 The PMA protocol
   19.3.1 What should the protocol contain?
      Box 19.3.a: Elements of a PMA protocol
   19.3.2 Publication of the protocol
19.4 PMA data collection
19.5 PMA analysis issues
   19.5.1 General approach
   19.5.2 Interim analysis and data monitoring
19.6 Chapter information
   Box 19.6.a: The Cochrane Prospective Meta-analysis Methods Group
19.7 References

20 Qualitative research and Cochrane reviews
20.1 Introduction
20.2 Incorporating evidence from qualitative research in Cochrane Intervention reviews: concepts and issues
   20.2.1 Definition of qualitative research
   20.2.2 Using evidence from qualitative research in Cochrane reviews
   20.2.3 Considering qualitative studies that are identified within, or alongside, randomized controlled trials.
   20.2.4 Resource considerations
20.3 Qualitative evidence synthesis
   20.3.1 Exemplar of synthesizing qualitative evidence to supplement a Cochrane Intervention review: Directly Observed Therapy and Tuberculosis (TB)
      Box 20.2.a: Directly observed therapy and tuberculosis: a synthesis of qualitative evidence-summary
   20.3.2 Methodological issues
   20.3.2.1 Search strategies
   20.3.2.2 Critical appraisal
   20.3.2.3 Synthesizing evidence from qualitative research
   20.3.2.4 Choosing an appropriate method
   20.3.2.5 Approaches to integrating qualitative and quantitative evidence syntheses
   20.3.2.6 Conclusion
20.4 Contributions to this Chapter
   Box 20.4.a: The Cochrane Qualitative Research Methods Group
20.5 References
20.6 Further Selected Reading
   20.6.1 Qualitative Research – general
   20.6.2 Qualitative Methods
   20.6.3 Qualitative Literature Searching
   20.6.4 Synthesizing Qualitative Evidence
   20.6.5 Synthesizing qualitative and quantitative evidence
   20.6.6 Critical appraisal of qualitative studies
   20.6.7 Links

21 Reviews in health promotion and public health
21.1 Introduction
21.2 Study designs to include
21.3 Searching
21.4 Assessment of study quality and risk of bias
21.5 Ethics and inequalities
21.6 Context
21.7 Sustainability
21.8 Applicability and transferability
21.9 Contributions to this chapter
22 Overviews of reviews

22.1 Introduction
   22.1.1 Definition of Cochrane Overviews of reviews
   22.1.2 Rationale for Cochrane Overviews
      Table 22.1.a: Reasons for overviewing reviews and their suitability for publication as a Cochrane Overview

22.2 Preparing a Cochrane Overview of reviews
   22.2.1 Organizational issues
   22.2.2 Methodological issues
      Table 22.2.a: Comparison of methods between Cochrane Intervention reviews and Cochrane Overviews of reviews
   22.2.3 Updating Cochrane Overviews

22.3 Format of a Cochrane Overview
   22.3.1 Title and review information (or protocol information)
   22.3.2 Abstract
   22.3.3 Plain language summary
   22.3.4 Text of a Cochrane Overview
   22.3.5 Review and references
      22.3.5.1 References to reviews
      22.3.5.2 Other references
   22.3.6 Tables
      22.3.6.1 ‘Characteristics of included reviews’ table
         Figure 22.3.a: Template for a ‘Characteristics of included reviews’ table
      22.3.6.2 ‘Overview of reviews’ table
         Figure 22.3.b: Template for an ‘Overview of reviews’ Table
      22.3.6.3 Other tables
   22.3.7 Figures
      Figure 22.3.c: Example of a ‘forest top plot’ comparing interventions for enuresis in children. This example was prepared using Microsoft Excel.

22.4 Chapter information

22.5 References
Index

absolute risk reduction (ARR) see risk difference
abstracts 4:4, 11:15-11:17
adverse effects 14:8
non-randomized studies 13:13
Overviews of reviews 22:8-22:9
searching 6:3, 6:13, 6:40, 6:41, 13:4, 14:8
selecting studies 7:3
accumulation of changes 3:7
acknowledgements 4:15, 22:15
ACR see assumed control risks
Additional tables 4:18, 8:43, 11:13, 15:16, 17:8
adherence 7:8, 12:9
adverse effects 14:1-14:13
data collection 7:9-7:10
definitions 14:2
drop-outs 14:5
eligibility criteria 14:3-14:5
narrow/broad focus 14:4-14:5
review questions 5:6-5:7
risk of bias/quality 14:8-14:11
searching 14:6-14:8
separate reviews 14:4
sources of information 14:6
strategies for addressing 14:3-14:4
Summary of findings tables 11:12
types of studies 14:6, 14:8-14:11
Adverse Effects Methods Group (AEMG) 14:11
advisory groups 2:7-2:8
AEMG see Adverse Effects Methods Group
aetiological research questions 13:7
agreement measures 7:4-7:5, 7:15
allied health-specific databases 6:1-6:2
allocation concealment 8:6, 8:24, 8:27-8:29
results sections 4:12
Risk of bias tool 7:14, 8:5, 12:19
Risk of bias tool 8:7-8:9, 8:12, 8:17-8:19, 8:29-8:31
analysis of covariance (ANCOVA) 9:21
prospective meta-analyses 19:5, 19:6-19:7
ANCOVA see analysis of covariance
appendices 4:23
search strategies 6:41, 6:42
applicability
discussion sections 4:13-4:14
interpreting results 12:8-12:9
Overviews of reviews 22:14
public health and health promotion 21:8-21:9
Applicability and Recommendations Methods Group (ARMG) 12:20
ARR (absolute risk reduction) see risk difference
as-treated analyses 8:36
assessing a review as up to date 3:8-3:9, 3:11, 4:3, 22:16
assumed control risks (ACR) 11:11, 11:12, 12:13, 12:14-12:15
attrition bias 8:8-8:9, 8:13-8:14, 8:31-8:37
authors’ conclusions see conclusions
authorship 3:5, 3:7, 3:8, 4:2-4:3
available case analysis 16:7, 16:8, 16:9-16:10
background sections 4:5-4:6, 22:9-22:10
baseline imbalance 8:41
baseline risk see control group risk
Bayesian methods 8:24, 16:29-16:31
before-and-after studies 13:2, 21:4
bias see publication bias; reporting bias; risk of bias
Bias Methods Group (BMG) 10:24
bibliographic databases 6:3-6:10
binary outcome data see dichotomous outcome data
biologic variation 12:9
biology-specific databases 6:7
blinding 8:6, 8:29-8:31
results sections 4:12
review authors 7:14, 8:5, 12:19
Risk of bias tool 8:7-8:9, 8:12, 8:17-8:19, 8:29-8:31
blocked randomization 8:7, 8:26, 8:41
BMG see Bias Methods Group
Boolean operators 6:31, 6:39
broad questions 5:8-5:9
Campbell and Cochrane Economics Methods Group (CCEMG) 15:4, 15:12, 15:17, 15:22, 17:12
Campbell Collaboration 8:43
Campbell Coordinating Groups 20:11
Campbell Equity Methods Group 21:5
carry-over effects 16:15-16:18
case reports 14:6, 14:10-14:11
case series 13:3, 14:6
CBA see cost-benefit analysis
CBT see cognitive behavioural therapy
CCEMG see Campbell and Cochrane Economics Methods Group
CCTs see controlled clinical trials
CDSR see Cochrane Database of Systematic Reviews
CEA see cost-effectiveness analysis
CENTRAL see Cochrane Central Register of Controlled Trials
central randomization 8:29
Centre for Reviews and Dissemination (CRD)
6:14, 15:9-15:11, 15:12
CGR see control group risk
change scores 7:17, 9:21-9:22
standard deviations 16:4-16:7
changing review questions 5:9-5:10
Characteristics of studies tables 4:11-4:12, 4:17-4:18
economics evidence 15:16
excluded studies 4:12, 4:17, 7:4
included studies 4:11-4:12, 4:17, 11:2, 15:26
ongoing studies 4:12, 4:18
Overviews of reviews 22:12, 22:16-22:17
studies awaiting classification 14:12, 14:18
checklists 8:4
CINAHL database 6:8, 20:7
citation
bias 10:2, 10:8-10:9
indexes 6:9
versions 3:3-3:5, 3:6-3:8, 4:4
citing
protocols 4:6
reviews 2:11-2:12
clinical event pathways 15:6-15:7
clinical trials see randomized trials
cluster-allocated studies 13:16-13:17
see also cluster-randomized trials
clustering 16:14
cluster-randomized trials 9:14, 16:10-16:14
effective sample sizes 16:12-16:13
inflating standard errors 16:13-16:14
meta-analysis 16:12-16:14
methods of analysis 16:12
public health and health promotion 21:2-21:3, 21:6
risk of bias 16:11-16:12
sensitivity analyses 9:38
CMR see Cochrane Methodology Register
Cochrane, Archie 1:2, 15:2
Cochrane Central Register of Controlled Trials
Cochrane Collaboration 1:1-1:3
maintenance of Cochrane reviews 3:2
preparation of Cochrane reviews 2:1, 2:6, 2:11-2:14
principles 1:2, 1:5
publication of Cochrane reviews 1:3
structure 1:2
Cochrane Database of Systematic Reviews (CDSR) 1:3
citation versions 3:3-3:5
citing 2:11-2:13
dates 3:8, 4:3-4:4
Overviews of reviews 22:2
prospective meta-analyses 19:7
protocols 2:2-2:3, 2:5-2:6
searching see Cochrane Library
withdrawn reviews 3:13
Cochrane Health Equity Field 21:5
Cochrane Library 1:3
Cochrane Review Groups 2:9-2:11
ecconomics evidence 15:10
feedback 3:15
Overviews of reviews 22:2
searching 6:4-6:5, 6:21, 6:22, 6:25-6:26, 6:32
Cochrane Methodology Register (CMR) 1:3
Cochrane Review Groups (CRGs) 1:2, 1:4
economics evidence 15:4
guidance and support 2:5-2:6, 2:8-2:11, 2:14, 4:8, 4:15, 5:8
Overviews of reviews 22:1-22:2, 22:
plain language summaries 11:17-11:18
prospective meta-analyses 19:7
public health and health promotion 21:4
qualitative research 20:5, 20:10-20:11
searching 4:8-4:9, 6:2-6:3, 6:7, 6:11, 6:20, 6:23-6:25, 6:29, 6:41
statisticians 9:39-9:40
Cochrane reviews
Diagnostic test accuracy 1:4, 2:8
Intervention 1:3-1:5, 2:2-2:4
Methodology 2:8
Overviews of reviews 2:8, 22:1-22:21
coding schemes 7:13
cognitive behavioural therapy (CBT) 17:4
cohort studies 13:2, 13:7, 13:20, 14:6, 14:9
collaborations
individual patient data 18:1, 18:2-18:3
prospective meta-analyses 19:4
see also Cochrane Collaboration
combining studies see meta-analysis
combining subgroups/intervention groups 7:21
comments and criticisms see feedback
community healthcare-specific databases 6:8
completeness of evidence 4:13-4:14
concealment of allocation see allocation concealment
conclusions 4:14, 12:18-12:20
abstract 11:16, 11:17
changed 3:4, 3:6-3:8
economics evidence 15:21-15:22
Overviews of reviews 22:9, 22:14-22:15
qualitative research 20:6-20:7
conditional outcomes 16:10
conference abstracts/proceedings 6:13
confidence intervals 12:9-12:11
continuous outcome data 7:18-7:20, 12:10
data extraction 7:18-7:20, 7:25-7:26
dichotomous outcome data 7:16, 12:10
forest plots 11:4
rare events 16:33
Summary of findings tables 11:13
confidentiality 18:3-18:4, 19:4
conflicts of interest see declarations of interest
confounding
GRADE/quality of evidence 12:4, 12:7
heterogeneity 9:35
indirect comparisons 16:26
public health and health promotion 21:2
consensus 7:15
consistency see heterogeneity
consumer involvement 2:6-2:7
contact persons 4:3
contents of Cochrane reviews 2:2-2:4, 4:1-4:24
abstracts 4:3
appendices 4:23
data and analyses 4:20-4:21
feedback 4:23
figures 4:21-4:22
plain language summaries 4:4-4:5
protocol information 4:1-4:5
review information 4:1-4:5
studies and references 4:19-4:20
tables 4:16-4:17
text 4:5-5:17
titles 4:2
context 12:9, 21:6-21:7
continuous outcome data 9:6, 9:10-9:122
confidence intervals 7:17-7:20, 12:10
counts 7:23
data extraction 7:16-7:22, 7:23-7:24
forest plots 11:3-11:5
funnel plots 10:19
individual patient data 18:6,18:7
intention to treat 16:9-16:10
interpreting results 12:16-12:17
meta-analysis 9:20-9:23, 9:38
non-randomized studies 13:25
Overviews of reviews 22:18
results sections 11:3-11:5, 11:12, 12:10, 12:16-12:17
risk of bias 8:14, 8:35, 8:38
Summary of findings tables 11:12
see also patient-reported outcomes
contour-enhanced funnel plots 10:14-10:16
contributions of authors 4:15-4:16
control group risk (CGR)
effect measures 9:6-9:9
meta-regression 9:36-9:37
interpreting results 11:10-11:11, 11:12-11:13, 12:13, 12:15
see also assumed control risk
controlled
before-and-after studies 13:2
vocabulary 6:29-6:30, 14:7, 17:7-17:8
copyright 6:3
correlation coefficients 16:5-16:7, 16:13-16:14, 16:20-16:21
correspondence with investigators 7:11, 7:13, 8:6
cost data 15:18-15:19
cost-benefit analysis (CBA) 15:2, 15:3, 15:7
cost-effectiveness analysis (CEA) 15:2, 15:3, 15:7, 15:20
cost-utility analysis (CUA) 15:2, 15:3
count data 9:6, 9:12-9:13
data extraction 7:22-7:23
meta-analysis 9:24-9:25, 16:32
zero-cell 16:32
covariates 9:33-9:34, 13:26
Cox model 7:24, 9:25, 13:25
CRD see Centre for Reviews and Dissemination
CRGs see Cochrane Review Groups
critical appraisal
qualitative research 20:8, 20:16-20:17
see also quality, risk of bias
cross-over trials 9:14, 16:14-16:21
eligibility criteria 16:15
meta-analysis 16:17-16:21
methods of analysis 16:17
risk of bias 16:15-16:17
sensitivity analyses 9:38
unit of analysis errors 9:15, 16:17
cross-sectional studies 13:3, 13:20
CUA see cost-utility analysis
cultural factors 12:2, 12:9
DARE see Database of Abstracts of Reviews of Effects
data collection 7:5-7:13
abstracts 11:15, 11:16
economics evidence 15:11-15:12, 15:14-15:15
forms 7:11-7:13
individual patient data 18:4-18:5
interventions 7:6, 7:7, 8-7:9
methods of studies 7:5-7:6, 7:7
methods sections 4:9-4:11
non-randomized studies 13:14-14:17
outcomes 7:5-7:6, 7:9-7:10
participants 7:5-7:7
prospective meta-analyses 19:6-19:7
results 7:5-7:6, 7:10
risk of bias 8:5-8:6
sources of data 7:5-7:6, 7:11
sustainability 21:7
effective 7:16, 7:20, 7:24-7:26
extraction 7:13-7:26
consensus 7:15
continuous outcome data 7:16-7:22, 7:23
conversion to desired format 7:16-7:26
counts 7:22-7:23
dichotomous outcome data 17:16, 7:23
estimates of effects 7:24-7:26
multiple reports 7:14-7:15
ordinal outcome data 7:22
Overviews of reviews 22:11
results 7:16-7:26
time-to-event data 7:23-7:24
management 7:26
individual patient data 18:4-18:5
Overviews of reviews 22:11
prospective meta-analyses 19:6, 19:7, 19:8
synthesis see meta-analysis
time to event see time-to-event data
types 9:6-9:14
see also continuous outcome data; count data; dichotomous outcome data; ordinal outcome data; rate data; time-to-event data
Data and analysis section 4:20-4:21, 11:3-11:5, 11:14
Database of Abstracts of Reviews of Effects (DARE) 1:3, 6:14
dates 3:8-3:10, 4:3-4:4, 6:32-6:33
declarations of interest 2:13-2:14, 4:16, 22:15
derivative products 2:13
DerSimonian and Laird method see random-effects methods
descriptions of condition/intervention 4:6
design-specific risk of bias 8:40
detection bias 8:7
diagnostic test accuracy 1:4
dichotomous outcome data 9:6-9:10
confidence intervals 7:16, 12:9-12:10
counts 7:23
data extraction 7:16, 7:23
funnel plots 10:12, 10:19
individual patient data 18:6, 18:7
intention to treat 16:8-16:9
interpreting results 12:12-12:16
non-randomized studies 13:25
patient-reported outcomes 17:10
risk of bias 8:14, 8:22, 8:34, 8:38
Summary of findings tables 11:10-11:11, 11:13
difference measures 7:25, 9:9, 9:10-9:11, 12:12-12:16
difference in means 9:10-9:11, 12:16-12:17
cross-over trials 16:18-16:19
funnel plots 10:19-10:20
meta-analysis 9:20-9:23
differential diagnostic activity 8:42
directly observed therapy (DOT) 20:5-20:7
directness see indirect evidence
dissertations databases 6:6-6:10
dose-response analyses 9:37, 12:4, 12:7-12:8
DOT see directly observed therapy
double-blinding see blinding
Downs and Black instrument 13:22
drop-outs see incomplete outcome data
Drummond checklist 15:13-15:15
duplicated data see multiple reports
eye 8:40-8:41
economics evidence 15:1-15:25
clinical event pathways 15:6
data analysis 15:14-15:19
data collection 15:11-15:12, 15:14-15:15
eligibility criteria 15:8-15:9, 15:11, 15:4
evaluation types 15:2-15:4
meta-analysis 15:18-15:19
model development 15:19
outcomes 15:7
reporting bias 15:20
review questions 5:7, 15:5-15:7
risk of bias/quality 15:12-15:16, 15:17
role and relevance 15:1-15:4
searching 15:9-15:11
strategies for addressing 15:8-15:9
editorial procedures 2:9, 3:13
education-specific databases 6:8
effect estimates 7:24-7:26, 9:16-9:18
measures 4:9, 9:4-9:14, 9:29
modification 9:32
size 9:11
Effective Practice and Organisation of Care
(EPOC) Group 21:4
effectiveness 13:7, 21:4-21:6
Effectiveness and Efficiency (Cochrane) 15:2
effects of interventions section 14:13
Electronic Information for Libraries (eIFL) 6:4, 6:12
eligibility criteria 5:1-5:9, 7:1-7:4
abstracts 11:15-11:16
adverse effects 14:3-14:5
cross-over trials 16:15
data collection 7:5, 7:11
economics evidence 15:8, 15:11, 15:13-
15:14
excluded studies 7:4
measures of agreement 7:4
methods sections 4:7
multiple reports 7:2
non-randomized studies 13:5-13:8, 13:14,
13:28
Overviews of reviews 22:3-22:5, 22:7,
Cochrane Review Groups 2:10
prospective meta-analyses 19:1-19:2, 19:5,
19:6
qualitative research 20:6
references 4:19
searching 6:28
selection process 7:1-7:5
sensitivity analyses 9:38
studies versus reports 7:2
unpublished studies 10:10-10:11
updates and amendments 3:11
EMBASE 6:3-6:6, 6:2
adverse effects 14:7-14:8
CENTRAL 16:31
economics evidence 15:10
non-randomized studies 13:12
qualitative research 20:7
reporting bias 10:8
searching for reviews 6:14
searching for studies 6:25-6:30, 6:37
EPICOT acronym 12:18
EPOC see Effective Practice and Organisation of
Care
EPPI see Evidence for Policy and Practice
Information
errata 3:6-3:7, 6:33-6:34
estimates of effect see effect estimates
ethics 8:43, 21:4-21:6
Evers checklist 15:14, 15:15
Evidence for Policy and Practice Information
(EPPI) Centre 20:8, 20:9, 20:17
excluded studies 7:4
Overviews of reviews 22:15
reporting bias 10:10-10:11
results sections 4:12
sensitivity analyses 9:29-9:30, 9:37
table 4:17, 4:17-4:18
see also eligibility criteria
exclusions 8:6, 8:9, 8:13-8:14, 8:31-8:33
see also intention to treat
explanatory variables 9:33-9:34
external funding 4:23, 10:6-10:7
factorial trials 16:21-16:22, 16:25-16:26
fail-safe N 10:22
false negatives 9:32
false positives 9:32-9:33, 10:19
feedback 3:15, 4:22
figures 4:21-4:22, 11:15-11:17
Overviews of reviews 22:20
risk of bias 8:19-8:21, 8:21
see also forest plots; funnel plots
file drawer problem 10:3
first published dates 4:4
fixed-effect method 9:16, 9:29
confidence intervals 9:29, 12:9-12:11
forest plots 11:3-11:5
reporting bias 10:20-10:21
sensitivity analyses 9:38, 10:20-10:21
forest plots 4:22, 11:3-11:5
figures 11:5-11:6
heterogeneity 9:28, 9:33
non-randomized studies 13:26-13:27
results sections 11:14
risk of bias 8:21
see also forest top plots
forest top plots 11:6, 22:20
format of Cochrane reviews 2:2-2:4
see also contents of Cochrane reviews
fraudulent studies 6:33
free-text terms 6:29-6:30, 14:8, 17:7
full economic evaluations 15:2-15:4
full-text electronic journals 6:11-6:12
full-text reports 7:2
functional status 17:3
funding
preparation of Cochrane reviews 2:11
risk of bias 8:42
funnel plots 10:11-10:20
figures 4:22, 11:6
non-randomized studies 13:12
tests for asymmetry 10:16-10:20
GDP see gross domestic product
generic inverse-variance outcome data 9:17-9:18
cluster-randomized trials 16:12, 16:13-
16:14
combining dichotomous and continuous
outcome data 9:23
counts and rates 9:25

cross-over trials 16:18-16:20, 16:21
data extraction 7:24-7:25
forest plots 11:5
non-randomized studies 13:26-13:27
ordinal outcome data 9:24
RevMan 9:17, 9:25, 11:3
see also inverse-variance meta-analysis
GRADE 11:13, 12:3-12:4, 12:20
non-randomized studies 13:29
GRADEprofiler software 11:9-11:10
graphs see figures
grey literature
databases 6:10-6:11, 6:19, 6:42
reporting bias 10:10-10:11
gross domestic product (GDP) 15:16
group-allocated studies see cluster-allocated studies

handsearching 6:11, 6:21
harms see adverse effects
hazard ratio 9:13, 9:25, 13:26
headings 4:5
health equity 21:4-21:6
Health InterNetwork Access to Research Initiative (HINARI) 6:4, 6:12
health promotion-specific databases 6:7
see also public health and health promotion
health status 17:3-17:4
Health Technology Assessment Database (HTA) 6:14
health-related quality of life (HRQOL) 17:3-17:6, 17:7, 17:10-17:12
health-specific databases 6:6-6:9
healthcare librarians 6:20
heterogeneity 9:27-9:37
addressing 9:28-9:30
analysis plans 9:5, 9:34, 9:36
baseline risk 9:36-9:37
definitions 9:27
dichotomous outcome data 9:19-9:20
dose-response analyses 9:37
economics evidence 15:17-15:18
forest plots 11:4-11:5
GRADE/quality of evidence 12:4, 12:5
I-squared 9:28, 9:31
identification and measurement 9:28
interaction and effect modification 9:32
meta-regression 9:33-9:37
methods sections 4:10
multi-arm studies 16:24-16:25
Overviews of reviews 22:18

rare events 16:14
reporting bias 10:15, 10:19
subgroup analyses 9:32-9:36
tau-squared 9:30, 10:19, 11:4-11:5
testing 9:28, 9:30-9:31
see also random-effects method
hierarchical models 16:21
highly sensitive search strategies 6:33-6:37, 6:39
HINARI see Health InterNetwork Access to Research Initiative
historically controlled studies 13:2
History tables 3:13-3:15, 4:4
homogeneity see heterogeneity
HRQOL see health-related quality of life
HTA see Health Technology Assessment Database
I-squared 9:28, 9:31
ICC see intracluster correlation coefficients
ICER see incremental cost-effectiveness ratio
ICMJE see International Committee of Medical Journal Editors
identifiers 4:19, 6:40, 7:6, 7:13
implications for practice/research 4:14-4:15, 12:18-12:19
imputations
change from baseline 9:22, 16:4-16:7
cluster-randomized trials 16:13
cross-over trials 16:18, 16:20-16:21
intention to treat 8:36-8:37, 16:3, 16:9-16:10
standard deviations 16:4-16:7
IMRG see Information Retrieval Methods Group
IMS see Information Management System
incomplete outcome data 8:6, 8:31-8:37
attrition/drop-out 8:6, 8:32, 14:5
exclusions 8:6, 8:9, 8:13-8:14
results sections 4:13
Risk of bias tool 8:7, 8:9, 8:13-8:14, 8:31-8:37
see also intention to treat; missing data; selective outcome reporting
incremental cost-effectiveness ratio (ICER) 15:7
index terms see controlled vocabulary
indirect evidence 12:4, 12:5
individual patient data (IPD) 7:11, 18:1-18:4
benefits and limitations 18:2, 18:6, 18:8
 collaborations 18:3, 18:3-18:4
confidentiality 18:3-18:4
data collection 7:11-7:13, 8:4
meta-analysis 16:31, 18:6
prospective meta-analyses 19:1-19:4
individual patient data meta-analysis methods
group (IPD MA MG) 18:3, 18:7, 18:8-18:9
inequalities 21:4-21:5
Information Management System (IMS) 2:8
Information Retrieval Methods Group (IRMG) 6:43, 13:14
integrity of interventions 5:6, 7:8-7:9, 21:8-21:9
intention to treat (ITT) 8:32-8:33, 16:7-16:10
interaction 9:32
interim analyses 8:41, 19:8
International Committee of Medical Journal Editors (ICMJE) 10:11
interpreting results 12:1-12:24
continuous outcome data 12:16-12:17
dichotomous outcome data 12:12-12:16
economics evidence 15:21
meta-regression 9:35-9:36
non-randomized studies 13:27-13:28
patient-reported outcomes 17:10-17:11
subgroup analyses 9:35-9:36
interquartile ranges 7:21
interrupted-time-series studies 13:2-13:3
interventions
background sections 4:5
Characteristics of studies tables 11:2
data collection 7:6, 7:8-7:9
eligibility criteria 4:7, 5:2-5:3, 5:8
integrity 5:6, 7:8, 21:8-21:9
review questions 5:2-5:3, 5:8-5:9
intracluster correlation coefficient (ICC) 16:14-16:14
inverse-variance meta-analysis 9:17-9:18
continuous outcome data 9:20-9:21
dichotomous outcome data 9:18-9:20
fixed-effect method 9:16
random-effects method 9:17, 9:23, 9:25
rare events 16:31-16:32, 16:33
RevMan 9:26
see also generic inverse-variance outcome data
IPD see individual patient data
IPD MA MG see individual patient data meta-analysis methods group
IRMG see Information Retrieval Methods Group
ITT see intention to treat
Joanna Briggs Institute (JBI) 20:8, 20:9, 20:17
journals 6:11-6:13, 7:11
kappa statistics 7:4-7:5, 7:15
L’Abbé plots 11:6
language
bias 6:2-6:3, 10:2, 10:9
restrictions 6:32-6:33
last edit date 3:9
last observation carried forward (LOCF) 8:36
licensing 6:3
location bias 10:2, 10:8
LOCF see last observation carried forward
log-rank statistics 7:24, 9:35
main outcomes 5:4-5:7, 11:7
main text sections see text sections
maintenance of Cochrane reviews 3:1-3:15
amendments 3:2, 3:5-3:6
citation versions 3:3-3:5, 3:6-3:8
conclusions changed 3:4, 3:6-3:8
dates 3:8-3:10
definitions 3:2-3:8
editorial procedures 3:13
feedback 3:15
frequency 3:2
History tables 3:13-3:15
major changes 3:3, 3:4
methods 3:12-3:13
protocols 2:1-2:2, 3:3-3:5
review questions 3:10-3:12, 5:9
splitting reviews 3:12
updates 3:2, 3:5, 3:6-3:7, 3:9-3:13
What’s new events 3:10, 3:13-3:15
withdrawn reviews 2:6, 3:4, 3:13, 4:17
major changes to protocols 3:4, 3:5
Mantel-Haenszel methods 9:18, 9:33
forest plots 11:14
non-randomized studies 13:25
rare events 16:32, 16:34
RevMan 9:26, 11:3
test for subgroup differences 9:33
masking see blinding
matching 13:24
mean difference see difference in means;
standardized mean difference
measurement scales see scales
measures of agreement 7:4-7:5, 7:15
medians 7:21, 11:5
MEDLINE 6:1-6:9, 6:19
abstracts of Cochrane reviews 4:4
adverse effects 14:7
CENTRAL 6:21-6:22
citation versions 3:3
economics evidence 15:9
handsearching 6:11
identifiers 4:19
non-randomized studies 13:12, 13:13
patient-reported outcomes 17:4, 17:7
qualitative research 20:7
reporting bias 6:2, 10:2, 10:8
searching for reviews 6:6-6:7
searching for studies 6:25-6:27, 6:33-6:40
meta-analysis 1:4, 9:1-9:43, 16:2-16:34
benefits and limitations 9:3-9:4
narrative summaries 9:2-9:3, 15:17-15:18
narrow questions 5:8-5:9
National Library of Medicine (NLM) 6:5, 6:21-6:23, 6:27
network meta-analysis see multiple-treatments meta-analysis
new citation versions 3:3-3:5, 3:6-3:8
Newcastle-Ottowa Scale 13:22, 13:27
next stage expected date 3:9, 4:4
NHS Economic Evaluation Database (NHS EED) 15:10-15:11, 15:12, 15:14, 15:18
NLM see National Library of Medicine
NNH see number needed to treat
NNT see number needed to treat
no longer updated date 41
non-randomized studies (NRS) 13:1-13:34
adverse effects 13:5, 13:8, 13:29, 14:5, 14:9-14:10
adjusted estimates 13:18, 13:21
aetiological research questions 13:7
data collection 13:4-13:17
generic inverse-variance data 13:24
interpreting results 13:27-13:28
precision 13:5-13:6
protocols 13:4-13:5, 13:2
public health and health promotion 21:2, 21:4
reporting bias 5:7, 13:12
searching 13:12-13:14
selecting studies 13:14-13:17
selection bias 13:4, 13:21
strength of evidence 13:29-13:30
NRS see non-randomized studies
NRS MG see Non-Randomized Studies Methods Group
number needed to treat (NNT) 9:6, 9:9, 9:19-9:20, 12:12-12:16, 12:17
nursing-specific databases 6:8
O – E and Variance data 9:18, 9:25, 9:26, 18:7 see also time-to-event data
objectives sections 4:6, 22:7, 22:10
observational studies see non-randomized studies
odds ratio (OR) 9:6-9:10
cluster-randomized trials 16:14
data extraction 7:24-7:26
forest plots 11:4-11:5
funnel plots 10:12, 10:18
interpreting results 12:12-12:14
log scales 7:25-7:26, 9:14, 9:16, 10:12
non-randomized studies 13:25, 13:26
ordinal outcome data 9:12, 9:23-9:24
rare events 16:32-16:34
RevMan 11:3-11:5
standardized mean difference 9:22-9:23, 12:17
Summary of findings tables 11:10-11:11, 11:13
ongoing studies 4:18, 4:19, 6:15-6:20
ordinal outcome data 9:6, 9:11-9:12
data extraction 7:22
meta-analysis 9:23-9:24
sensitivity analyses 9:38
OR see odds ratio
outcomes
adverse effects 5:6-5:7, 14:1-14:5
change from baseline 7:17-7:18, 9:21-9:22
Characteristics of studies tables 11:2
Data and analysis section 4:20-4:21
data collection 7:5-7:6, 7:9-7:10
economics evidence 15:7
eligibility criteria 5:2, 5:4-5:7
GRADE/quality of evidence 12:2-12:3
grouping in Risk of bias tool 8:8
main 4:8, 5:5-5:6, 11:7
methods sections 14:7-14:8
missing see incomplete outcome data
multiple 16:28-16:29
patient-reported 17:1-17:14
primary 4:7, 5:6
reporting bias see selective outcome
reporting
review questions 5:4-5:7
risk of bias summarization 8:20, 12:6-12:7
secondary 4:8, 5:6
Summary of findings tables 4:8, 5:6, 11:7-11:8, 11:12
advisory groups 2:7-2:8
commercial sponsorship 2:13-2:14
consumer involvement 2:6-2:7
declarations of interest 2:13-2:14, 4:16, 22:15
editorial procedures 2:9, 3:13
format of Cochrane reviews 2:3-2:4
funding 2:11
logistics 2:5-2:11
motivation 2:5
permission to publish 2:11-2:12
protocols 2:1-2:2, 2:5-2:6
publication in journals and books 2:11-2:13
resources 2:10-2:11, 13:30, 14:2, 14:4, 18:3, 19:3, 20:5
review teams 2:6-2:8
software 2:8, 4:1-4:2, 11:10
timeline 2:10, 2:11
topic and scope 2:5
training 2:9
presentation of results see results sections;
Summary of findings tables
primary outcomes 4:7, 5:6, 8:15
PRO MG see Patient-Reported Outcomes
Methods Group
PROGRESS acronym 21:4-21:6
proportional odds model 9:12, 9:23-9:24
PROs see patient-reported outcomes
prospective meta-analyses (PMAs) 19:1-19:11
competitions 19:4
data collection 19:6-19:7
definitions 19:1-19:4
eligibility criteria 19:1-19:7
meta-analysis 19:4-19:7, 19:8
multi-centre trials 19:2-19:3
protocols 19:4-19:7
Prospective Meta-analysis Methods Group
(PMA MG) 19:1, 19:3 19:9
prospective trial registration 10:1
protocol information 4:2-4:4
protocols
amendments 3:3-3:5
citation versions 3:3-3:4, 3:5
differences with reviews 4:16-4:17
economics evidence 15:4, 15:11
first published date 4:3
major change 3:5
meta-analysis 9:5-9:6
multiple analyses 16:1, 16:29
outline 2:2-2:3
Overviews of reviews 22:14
prospective meta-analyses 19:4-19:7
rationale 2:1-2:2
registration 2:5-2:6
proximity operators 6:32
psychiatry-specific databases 6:8-6:9
psychology-specific databases 6:8-6:9, 6:10
PsycINFO 6:9, 6:10, 20:7
publication and health promotion (PHHP)
21:1-21:2
applicability 21:8-21:9
cost 21:6-21:7
economics evidence 12:4, 12:6
multiple 10:2, 10:7-10:8
review questions 5:7
time lag bias 10:2, 10:5-10:6
trial registries 10:11
see also reporting bias
publication policies 2:11-2:13, 18:3, 19:7
published notes 4:17
PubMed 6:5, 6:40
see also MEDLINE
Purchasing Power Parities (PPP) 15:16
QALY see quality-adjusted life years
QOL see quality of life
QRMG see Qualitative Research Methods Group
qualitative research 20:1-20:18
critical appraisal/quality 20:8, 20:16-20:17
definitions 20:2-20:3
directly observed therapy 20:5-20:7
eligibility criteria 20:6
implementation of interventions 20:4-20:5, 20:6
integrate with quantitative research 20:9-20:10, 20:16
mixed methods approach 20:3, 20:4-20:5
public health and health promotion 21:2, 21:3
randomized trials 20:4-20:5
resources 20:5, 20:14-20:18
review questions 20:3
strategies for addressing 20:3-20:5
synthesis 20:4, 20:5-20:10, 20:15-20:16
Qualitative Research Methods Group (QRMG)
20:2, 20:10-20:11
quality

adverse effects 14:8-14:11
abstracts 6:3, 6:13, 6:40, 6:41, 13:14, 14:8
adverse effects 14:6-14:8
dates 3:9, 3:10, 4:3-4:4
documenting 4:8, 6:41
economics evidence 15:9-15:11
eligibility criteria 6:28
managing references 6:39-6:41
methods sections 4:6-4:11, 6:41-6:42
non-randomized studies 13:12-13:14
Overviews of reviews 22:7, 22:11
patient-reported outcomes 17:7-17:8
planning 6:20-6:27
public health and health promotion 21:2-21:3
qualitative research 20:4-20:5, 20:6, 20:7, 20:15
references 6:14-6:15
reporting bias 6:3, 10:8, 10:10
results sections 4:11, 6:42
sources 6:3-6:20
bibliographic databases 6:3-6:10
Cochrane Library 6:4-6:5, 6:21, 6:22, 6:24, 6:25-6:26, 6:31-6:32
EMBASE 6:5, 6:14, 6:21, 6:25-6:30, 6:36-6:37
grey literature 6:10, 6:19, 6:42
journals 6:11-6:15
MEDLINE 6:5, 6:14, 6:21, 6:25-6:30, 6:36-6:37
ongoing/unpublished studies 6:15-6:19
strategies 6:28-6:29
Boolean operators 6:31, 6:39
examples 6:37-6:38
filters 6:33-6:37
proximity operators 6:32
restrictions 6:32-6:33
search filters 6:33-6:37
sensitivity and precision 6:29, 6:34-6:37, 6:39
search interfaces 6:28-6:29
structure 6:28
subject terms 6:29-6:30
updating 6:37
titles 6:3, 13:14, 14:8
Trials Search Co-ordinators 6:2-6:3, 6:7, 6:11, 6:20, 6:24-6:25, 6:40, 6:42
secondary outcomes 4:8, 5:6
selection bias 8:7, 8:24, 8:28
funnel plots 10:14
non-randomized studies 13:4, 13:18, 13:31
risk of bias 8:23
search strategy 6:29, 6:34-6:37, 6:39
sequence generation 8:6-8:12, 8:17-8:18, 8:24-8:27
results sections 4:12
Risk of bias tool 8:7-8:8, 8:11-8:16, 8:17-8:18, 8:19, 8:39-8:40
sensitivity analyses 9:37-9:39
cluster-randomized trials 16:14
cross-over trials 16:20-16:21
individual patient data 18:8
methods sections 4:11
missing data 16:4, 16:9-16:10
non-randomized studies 13:26
reporting bias 10:20-10:23
risk of bias 8:23
small study effects 10:14-10:16, 10:18, 10:20-10:23, 13:12
SMD see standardized mean difference
SMG see Statistical Methods Group
social healthcare-specific databases 6:8
social science-specific databases 6:8-6:9
socio-economic data 21:4-21:6
software 2:8, 4:1-4:2, 11:10
sources of support 2:13-2:14, 4:23
splitting reviews 3:12, 5:8
standard deviations
cross-over trials 16:17-16:20
data extraction 7:16, 7:18-7:20, 7:22
missing 16:4-16:7
standard errors
cross-over trials 16:13-16:14
cross-over trials 16:20-16:21
data extraction 7:16, 7:18-7:20, 7:25-7:26, 9:28
meta-analysis 9:17, 9:21, 9:25
standardized mean difference (SMD) 9:11, 12:16-12:17
change from baseline 9:21-9:22
correlation 16:11
cross-over trials 16:19
funnel plots 10:19
interpreting results 12:16-12:17
patient-reported outcomes 17:9, 17:11
statistical
heterogeneity see heterogeneity
significance 12:11-12:12
tests
funnel plot asymmetry 10:16-10:20
unclear risk of bias 8:10-8:16, 8:21-8:22, 8:27
unit-of-analysis errors 9:14-9:16, 16:10-16:11, 16:12, 16:17
unpublished studies 6:15-6:20, 10:10-10:11
unrestricted randomization 8:25
up-to-date reviews 3:8-3:9, 4:3
updates 3:2, 3:4, 3:5-3:6, 3:8-3:15
methods sections 4:11
Overviews of reviews 22:8
searching 6:37, 6:39
validation of instruments 17:6-17:8
validity see risk of bias
variant spellings 6:30-6:31
vote counting 9:26
web searching 6:15
weighted mean difference (WMD) 9:10-9:11
weights
quality 8:4, 8:24
well-being 17:2, 17:3
What's new events 3:10, 3:13-3:15, 4:4
WHO see World Health Organization
wildcards 6:30-6:31
WinBUGS software 16:29-16:31
withdrawals see incomplete outcome data
WMD see weighted mean difference
World Health Organization (WHO) 6:16
zero frequencies 16:32-16:33